VEA
VRDN icon

Virtus ETF Advisers’s Viridian Therapeutics VRDN Stock Holding History

Virtus ETF Advisers’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,952
Closed -$75.8K – 794
2024
Q4 		$75.8K Sell
3,952
-3,059
-44% -$66.5K 0.03% 346
2024
Q3 		$160K Buy
7,011
+127
+2% +$2.08K 0.07% 316
2024
Q2 		$89.6K Buy
6,884
+2,405
+54% +$33.3K 0.04% 361
2024
Q1 		$78.4K Sell
4,479
-308
-6% -$5.97K 0.04% 396
2023
Q4 		$104K Buy
4,787
+1,215
+34% +$19.2K 0.07% 342
2023
Q3 		$54.8K Sell
3,572
-358
-9% -$6.83K 0.03% 410
2023
Q2 		$93.5K Buy
3,930
+307
+8% +$7.87K 0.06% 410
2023
Q1 		$92.2K Sell
3,623
-1,394
-28% -$44.7K 0.05% 355
2022
Q4 		$147K Buy
+5,017
New +$116K 0.08% 352

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Virtus ETF Advisers's VRDN Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Viridian Therapeutics (VRDN) in Q1 2025, closing a stake of 3,952 shares — an estimated $75.8K sold.

Virtus ETF Advisers first reported a position in VRDN in Q4 2022 and held it in 9 quarters. The position peaked at $160K in Q3 2024. 176 funds tracked by Wall St. Rank hold VRDN as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Viridian Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,952 Viridian Therapeutics shares in Q1 2025, an estimated $75.8K.
  • Virtus ETF Advisers first reported a position in Viridian Therapeutics in Q4 2022 and held it in 9 quarters.
  • Virtus ETF Advisers's Viridian Therapeutics position peaked at $160K in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.